AU2008265045B2 - Phenothiazine compounds for treating Mild Cognitive Impairment - Google Patents

Phenothiazine compounds for treating Mild Cognitive Impairment Download PDF

Info

Publication number
AU2008265045B2
AU2008265045B2 AU2008265045A AU2008265045A AU2008265045B2 AU 2008265045 B2 AU2008265045 B2 AU 2008265045B2 AU 2008265045 A AU2008265045 A AU 2008265045A AU 2008265045 A AU2008265045 A AU 2008265045A AU 2008265045 B2 AU2008265045 B2 AU 2008265045B2
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
alkyl
aliphatic
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008265045A
Other languages
English (en)
Other versions
AU2008265045A1 (en
Inventor
Serena Deiana
Elizabeth Anne Goatman
Dominic Venay Harbaran
Alison Dorothy Murray
Gernot Riedel
Roger Todd Staff
Claude Michel Wischik
Damon Jude Wischik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taurx Therapeutics Management Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of AU2008265045A1 publication Critical patent/AU2008265045A1/en
Application granted granted Critical
Publication of AU2008265045B2 publication Critical patent/AU2008265045B2/en
Assigned to TAURX THERAPEUTICS MANAGEMENT LTD. reassignment TAURX THERAPEUTICS MANAGEMENT LTD. Request for Assignment Assignors: WISTA LABORATORIES LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008265045A 2007-06-19 2008-06-17 Phenothiazine compounds for treating Mild Cognitive Impairment Active AU2008265045B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
US60/945,006 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (2)

Publication Number Publication Date
AU2008265045A1 AU2008265045A1 (en) 2008-12-24
AU2008265045B2 true AU2008265045B2 (en) 2014-02-27

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008265045A Active AU2008265045B2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating Mild Cognitive Impairment

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
CA2701075C (en) * 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
US9523045B2 (en) * 2013-01-30 2016-12-20 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
US10472340B2 (en) * 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030766A1 (en) * 1995-03-27 1996-10-03 F. Hoffmann-La Roche Ag Inhibition of tau-tau-association
WO2002055720A2 (en) * 2001-01-15 2002-07-18 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2006032879A2 (en) * 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2007110629A1 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd Inhibitors of protein aggregation
WO2007110627A2 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
WO2007110630A1 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
WO2008007074A2 (en) * 2006-07-11 2008-01-17 Wista Laboratories Ltd. Methods of synthesis and/or purification of diaminophenothiazinium compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030766A1 (en) * 1995-03-27 1996-10-03 F. Hoffmann-La Roche Ag Inhibition of tau-tau-association
WO2002055720A2 (en) * 2001-01-15 2002-07-18 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2006032879A2 (en) * 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
WO2007110629A1 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd Inhibitors of protein aggregation
WO2007110627A2 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
WO2007110630A1 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
WO2008007074A2 (en) * 2006-07-11 2008-01-17 Wista Laboratories Ltd. Methods of synthesis and/or purification of diaminophenothiazinium compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Callaway, Narriman Lee et al. "Methylene blue improves brain oxidative metabolism and memory retention in rats" Pharmacology, Biochemistry and Behavior (2004) Vol.77 No.1 pages 175 to 181 *
Callaway, Narriman Lee et al. "Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats" Neuroscience Letters (2002) Vol.332 No.2 pages 83 to 86 *
Dickey, Chad A. et al. "Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression" Molecular Degeneration (2006) Vol.1 pages 1 to 9 *
Riha, Penny D et al. "Memory facilitation by methylene blue: Dose-dependent effect on behavior and brain oxygen consumption" European Journal of Pharmacology (2005) Vol.511 No.2-3 pages 151 to 158 *
Wrubel, Kathryn M. et al. "The brain metabolic enhancer methylene blue improves discrimination learning in rats" Pharmacology, Biochemistry and Behavior (2007) Vol.86 No.4 pages 712 to 717 *

Also Published As

Publication number Publication date
JP5725605B2 (ja) 2015-05-27
EP2167095B1 (en) 2019-05-29
AU2008265045A1 (en) 2008-12-24
CA2690746C (en) 2018-01-02
US20100184752A1 (en) 2010-07-22
JP2010530403A (ja) 2010-09-09
DK2167095T3 (da) 2019-07-29
SI2167095T1 (sl) 2019-09-30
CA2690746A1 (en) 2008-12-24
PT2167095T (pt) 2019-08-06
CN101820884B (zh) 2013-08-28
BRPI0813670A2 (pt) 2014-12-30
HRP20191513T1 (hr) 2019-11-29
US9211294B2 (en) 2015-12-15
PL2167095T3 (pl) 2019-11-29
HUE045460T2 (hu) 2019-12-30
ES2739546T3 (es) 2020-01-31
WO2008155533A3 (en) 2009-02-19
EP2167095A2 (en) 2010-03-31
CN101820884A (zh) 2010-09-01
MY177001A (en) 2020-09-01
WO2008155533A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
AU2008265045B2 (en) Phenothiazine compounds for treating Mild Cognitive Impairment
Berk et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial
CN107810002B (zh) 左乙拉西坦的延时释放药物组合物
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
US11000519B2 (en) Pridopidine for treating drug induced dyskinesias
Mayeux Therapeutic strategies in Alzheimer's disease
EP2286810A1 (en) Pharmaceutical composition for treatment of fibromyalgia
US20240050427A1 (en) Treatments for obsessive compulsive disorder
CN114126622A (zh) 无色甲基硫堇鎓的治疗相互作用
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
CN114072154B (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
RU2824584C2 (ru) Метилтиониний в качестве усилителя когнитивной функции
WO2023243659A1 (ja) 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
HK40052880A (en) Extended release pharmaceutical compositions of levetiracetam
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト
HK1252154B (zh) 左乙拉西坦的延时释放药物组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)